Compare Invesco Solar ETF (TAN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Solar ETF vs GeneDx Holdings Corp — how do they compare? Invesco Solar ETF trades at $43.67 (market cap $894.08M), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2.3× Invesco Solar ETF's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Solar ETF for 34 Days and GeneDx Holdings Corp for 19 Days on average.
| TAN | WGS | |
|---|---|---|
Market Cap | $894.08M | $2.02B |
Volume | 370,994 | 734,640 |
Sector | Sector/Thematic | Health |
52-Week High | $73.95 | $167.51 |
52-Week Low | $43.00 | $34.51 |
Typical Hold Time | 34 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAN trades at $43.6, up 0.16% on the day, amid a bearish technical signal with moving averages and key indicators like ADX signaling sell conditions. The ETF faces headwinds from high borrowing costs impacting solar project financing, as noted in recent news. Financial ratios are unavailable, but the fund's high expense ratio of 0.7% and historical volatility are points of concern for investors.
Outlook remains cautious due to sector-specific risks like interest rate sensitivity and market saturation. Investment opportunities exist for those bullish on long-term solar adoption, but risks include policy uncertainty and cost pressures. Analyst sentiment is mixed, with some highlighting underperformance versus broader markets.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
